MAPT and Alzheimer disease: Immunotherapies directed at Aβ in AD patients can be effective in decreasing Aβ deposition in the brain, but it has not led to an improvement in clinical symptoms or decreased accumulation of Tau (Ostrowitzki et al., 2012; Doody et al., 2014; Salloway et al., 2014).